121 related articles for article (PubMed ID: 1337431)
1. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
[TBL] [Abstract][Full Text] [Related]
2. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Coley HM; Twentyman PR; Workman P
Cancer Chemother Pharmacol; 1989; 24(5):284-90. PubMed ID: 2547527
[TBL] [Abstract][Full Text] [Related]
3. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
[TBL] [Abstract][Full Text] [Related]
4. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
5. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
Cole SP; Downes HF; Mirski SE; Clements DJ
Mol Pharmacol; 1990 Feb; 37(2):192-7. PubMed ID: 1968221
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
7. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Eur J Cancer; 1990; 26(6):665-7. PubMed ID: 1975502
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
Smith PJ; Morgan SA; Fox ME; Watson JV
Biochem Pharmacol; 1990 Nov; 40(9):2069-78. PubMed ID: 2173600
[TBL] [Abstract][Full Text] [Related]
9. Intensely potent doxorubicin analogues: structure-activity relationship.
Farquhar D; Cherif A; Bakina E; Nelson JA
J Med Chem; 1998 Mar; 41(6):965-72. PubMed ID: 9526570
[TBL] [Abstract][Full Text] [Related]
10. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
Coley HM; Amos WB; Twentyman PR; Workman P
Br J Cancer; 1993 Jun; 67(6):1316-23. PubMed ID: 8099807
[TBL] [Abstract][Full Text] [Related]
11. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
Ford JM; Prozialeck WC; Hait WN
Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
[TBL] [Abstract][Full Text] [Related]
12. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
13. Tetramethylpiperidine-substitution increases the antitumor activity of the riminophenazines for an acquired multidrug-resistant cell line.
van Rensburg CE; Jooné GK; O'Sullivan JF
Anticancer Drug Des; 2000 Aug; 15(4):303-6. PubMed ID: 11200506
[TBL] [Abstract][Full Text] [Related]
14. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
Lothstein L; Hosey LM; Sweatman TW; Koseki Y; Dockter M; Priebe W
Oncol Res; 1993; 5(6-7):229-34. PubMed ID: 7907237
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Mirski SE; Gerlach JH; Cole SP
Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
[TBL] [Abstract][Full Text] [Related]
16. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells.
Yoshida M; Matsui Y; Ikarashi Y; Usui T; Osada H; Wakasugi H
Anticancer Res; 2007; 27(2):729-36. PubMed ID: 17465195
[TBL] [Abstract][Full Text] [Related]
18. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
20. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
